Comparison of platform technologies for assaying antibody to Ebola virus

Vaccine

Volumn 35, Issue 9, 2017, Pages 1347-1352

  Wilkinson, Dianna E ^a   Page, Mark ^a   Mattiuzzo, Giada ^a   Hassall, Mark ^a   Dougall, Thomas ^a   Rigsby, Peter ^a   Stone, Lindsay ^a   Minor, Philip ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Antibodies; Assay platforms; Ebola; Pseudotype neutralisation; Quantitation

Indexed keywords

GLYCOPROTEIN; HUMAN IMMUNOGLOBULIN; ZMAPP; VIRUS ANTIBODY;

ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; CLINICAL LABORATORY; CONTROLLED STUDY; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; IMMUNOFLUORESCENCE TEST; INTERMETHOD COMPARISON; LENTIVIRINAE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; VIRUS NEUTRALIZATION; WESTERN BLOTTING; WILD TYPE; WORLD HEALTH ORGANIZATION; BLOOD; COMPARATIVE STUDY; DEVICES; IMMUNOLOGICAL PROCEDURES; IMMUNOLOGY; PROCEDURES; SERODIAGNOSIS;

ANTIBODIES, VIRAL; EBOLAVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNOLOGIC TESTS; NEUTRALIZATION TESTS;

EID: 85011012907     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.11.083     Document Type: Article

References (3)

1. [1] WHO Ebola virus disease outbreak. < www.who.int/csr/disease/ebola/en/>; 2016. [accessed 22nd January 2016].
2. [2] WHO/ECBS. < http://apps.who.int/iris/bitstream/10665/197777/1/WHO_BS_2015.2280_eng.pdf>; 2015. [accessed 10th March 2016].
3. [3] van Griensven, J., Edwards, Tansy, de Lamballerie, Xavier, et al. Evaluation of convalescent plasma for Ebola virus disease in guinea. N Engl J Med 374 (2016), 33–42, 10.1056/NEJMoa1511812.